<DOC>
	<DOCNO>NCT01639833</DOCNO>
	<brief_summary>The objective study assess safety effectiveness Veriset™ Hemostatic Patch cardiovascular procedure compare Veriset™ Hemostatic Patch TachoSil® subject undergoing open cardiovascular surgery involve aorta ( e.g. , aortic valve replacement ( AVR ) , David procedure , Bentall procedure , abdominal aortic aneurysm repair , etc . ) , CABG .</brief_summary>
	<brief_title>A Premarket , Prospective , Randomized , Single-Blind Study Compare Veriset™ Hemostatic Patch TachoSil® Adjunct Hemostasis Subjects Undergoing Cardiovascular Surgery</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Hemostatics</mesh_term>
	<criteria>Subject provide informed consent . Subject ≥18 year age . Subject schedule surgery involve aorta ( e.g. , aortic valve replacement ( AVR ) , David procedure , Bentall procedure , abdominal aortic aneurysm repair , etc . ) , coronary artery bypass graft ( CABG ) topical hemostatic agent would use control bleed via open approach . Subject willing able comply aspect treatment evaluation schedule . Subject undergoing emergency surgery , i.e . lifesaving procedure perform patient imminent danger death . Subject history allergic reaction application human fibrinogen , human thrombin and/or collagen origin . Subject pregnant ( documented positive pregnancy test ) actively breastfeed . Subject estimate life expectancy le 6 month . Subject unwilling receive blood product . Subject schedule another plan cardiovascular surgery , subsequent surgery would jeopardize previous application study treatment . The subject participate another investigational drug device research study within 30 day enrollment . Subject appropriate Target Bleeding Site ( TBS ) define area bleed aorta coronary vessel hemostasis conventional method ineffective impractical , thus necessitate use topical hemostatic agent . TBS Bleeding Type 2 ( Oozing/Mild ) 3 ( Moderate ) . It possible hold pressure Veriset™ Hemostatic Patch TachoSil® least 3 minute . Incidental find preoperative exclusion criterion Subject appropriate TBS . TBS Bleeding Assessment Type 1 ( No bleeding ) 4 ( Severe/Surgical/Life Threatening ) . Subject active local infection surgical site . Investigator determine participation study may jeopardize safety welfare subject .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>